• Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to run preclinical studies on dual-payload ADCs.
• Work will test Akari’s PH1 RNA-splicing payload in combination with Whitehawk’s topoisomerase I inhibitor ADC platform for compatibility and synergy.
• Akari will lead study design, execution, evaluation; both companies will jointly review results to guide potential broader development talks.
• Collaboration starts immediately; interim data updates are expected as the studies progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210705PRIMZONEFULLFEED9765042) on July 21, 2026, and is solely responsible for the information contained therein.